This invention may be used to treat protozoan infections like malaria.
Many diseases caused by protozoan infection (e.g., malaria, leishmania, giardia, sleeping sickness, amoebic dysentery) are difficult and expensive to treat, use drugs with substantial side effects, or occur in remote regions with little access to facilities such as refrigeration. There is a great need for improved protozoan infection treatments as the incidence of drug resistance increases and protozoan infections remain an international leading cause of death.
The Tyr binding pocket of the essential and highly-conserved tyrosyl-tRNA synthetase (TyRS) protein differs at several key residues in fungi and animals from protozoans. This evolutionary event provides a unique opportunity for targeting selective antibiotic treatment of protozoan disease. Herein, we have identified a method for treating protozoan disease in humans including small molecule drugs that can be used to selectively target and eliminate these protozoans. These new drugs provide an alternative to existing therapies on the market, but are also essential as more drug resistant strains of protozoans, like malaria, emerge.
Specific to protozoan infections
Non-drug resistant small molecule therapies